pd-1 usually refers to the clinical use of “pd-1 inhibitors”, which may cause immune-associated pancreatitis in clinical practice. PD-1 inhibitors, including PD-1 antibodies and PD-L1 antibodies, are commonly used in immunotherapy for cancer. Because the interaction between PD-1 and PD-L1 can help tumors escape killing by the autoimmune system, pd-1 inhibitors can block the interaction between these two proteins, thus promoting the patient’s own immune system to kill tumors. At the same time, pd-1 inhibitors have the potential to prompt the patient’s own immune system to kill their own cells, resulting in autoimmune-related inflammation, such as immune pancreatitis, immune pneumonia, immune enteritis, immune hepatitis, and even immune myocarditis. If discomfort occurs during the use of pd-1 inhibitors, the patient should go to a regular hospital for further treatment and clarification of the cause of discomfort.